9.7 Pharmacogenomics Not applicable. Revised Protocol No.: 04 Date: 31-May-2019 121 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 122 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 123 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 124 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 125 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 126 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 127 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 128 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 129 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 130 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 131 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 132 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 133 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 134 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 135 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 136 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 137 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 138 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 139 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 140 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 141 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 142 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 143 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 144 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 145 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 146 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 9.9 Health Economics or Medical Resource Utilization and Health Economics Health Economics or Medical Resource Utilization and Health Economics parameters will not be evaluated in this study. 10 STATISTICAL CONSIDERATIONS 10.1 Sample Size Determination 10.1.1 Preliminary Safety Cohorts and Dose Escalation (Part A) Two single participants will be treated at BMS-986226 2 mg and 8 mg, respectively, in the Preliminary Safety Cohorts.